Carasent AB (publ) (STO:CARA)
Sweden · Delayed Price · Currency is SEK 23.40
-0.70 (-2.90%)
Mar 2, 2026, 5:09 PM CET
Carasent AB Revenue
In the year 2025, Carasent AB had annual revenue of 343.82M SEK with 24.91% growth. Carasent AB had revenue of 93.57M in the quarter ending December 31, 2025, with 15.64% growth.
Revenue
343.82M
Revenue Growth
+24.91%
P/S Ratio
4.80
Revenue / Employee
1.75M
Employees
196
Market Cap
1.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 343.82M | 68.56M | 24.91% |
| Dec 31, 2024 | 275.26M | 30.08M | 12.27% |
| Dec 31, 2023 | 245.18M | 38.59M | 18.68% |
| Dec 31, 2022 | 206.60M | 65.86M | 46.79% |
| Dec 31, 2021 | 140.74M | 73.11M | 108.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.97B |
| Swedish Orphan Biovitrum AB | 28.24B |
| Medicover AB | 25.74B |
| Sectra AB | 3.47B |
| Surgical Science Sweden AB | 992.34M |
| Stille AB | 567.63M |
| EQL Pharma AB | 425.75M |
| Devyser Diagnostics AB | 250.50M |